期刊文献+

西格列汀致不良反应国内外文献分析 被引量:6

Adverse drug reactions induced by sitagliptin:an analysis of domestic and foreign literature
原文传递
导出
摘要 目的:分析西格列汀药品不良反应的发生规律及特点,为安全合理用药提供参考。方法:检索2006年10月至2015年8月国内外学术期刊收载的西格列汀药品不良反应文献进行分析。结果:32例不良反应中,男性14例,女性18例,年龄60岁及以上患者17例(53.1%)。用药半年内发生29例(90.6%)。累及的器官或系统主要有皮肤及附件损害、肌肉骨骼系统损害及胃肠系统损害,临床表现有血管性水肿、横纹肌溶解及急性胰腺炎等。有1例患者因发生不良反应而死亡。结论:临床使用西格列汀要加强用药监测,关注药物相互作用,以减少不良反应的发生。 Objective: To analyze the general patterns and characteristics of adverse drug reactions( ADRs) induced by sitagliptin,providing a reference for clinical medicination. Methods: ADRs of sitagliptin reported in domestic and foreign academic journals from October 2006 to August 2015 were collected from CNKI,VIP and Pubmed,and analyzed statistically. Results: Totally 32 patients of ADRs induced by sitagliptin were collected,including 14 men and 18 women. Aged patients over 60 years-old showed a higher incidence( n = 17,53. 1%). Sitagliptin-induced ADRs occurred within six months in 29 patients. ADRs were chiefly mainfested as skin lesion and disorders of its appendages,musculi-skeletal system disorders and gastrointestinal system disorders.The main Clinical manifestations were angioedema,rhabdomyolysis and acute pancreatitis. One patient died of adverse reactions induced by sitagliptin. Conclusion: Clinicians should tightly monitor sitagliptin using and drug interactions to reduce the incidence of sitagliptin-induced ADRs.
作者 程军
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第14期1677-1680,共4页 Chinese Journal of New Drugs
关键词 西格列汀 不良反应 文献分析 sitagliptin adverse drug reactions literature analysis
  • 相关文献

参考文献16

  • 1万里燕,张策,郭伟宏,崔建,李红梅.西格列汀治疗2型糖尿病疗效和安全性的Meta分析[J].药物不良反应杂志,2013,15(6):306-313. 被引量:7
  • 2彭媛,王程程,唐利,张志勇.西格列汀上市后致皮肤不良反应的信号挖掘与评价[J].中国药房,2014,25(2):156-158. 被引量:16
  • 3NAKATANI K, KUROSE T, HYO T,et al. Drug-induced general- ized skin eruption in a diabetes mellitus patient receiving a dipep- tidyl peptidase-4 inhibitor plus metformin [ J ]. Diabetes Ther, 2012,3(1):14.
  • 4BROWN NJ, BYIERS S, CARR D, et al. Dipeptidyl peptidase- IV inhibitor use associated with increased risk of ACE inhibitor- associated angioedema [ J ]. Hypertension, 2009, 54 ( 3 ) : 516 - 523.
  • 5MAURER M, BADER M, BAS M, et al. New topics in bradyki- nin research [ J 1 ~ Allergy,2011, 66 ( 11 ) : 1397 - 1406.
  • 6KAO DP, KOHRT HE, KUGLER J. Renal failure and rhab- domyolysis associated with sitagliptin amt simvastatin use [ J ]. Diabet Med, 2008, 25(10) : 1229 - 1230.
  • 7VINCENT SH, REED JR, BERGMAN A J, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor[ 14C 1 sita- gliptinin humans[J~. DrugMetab Dispos, 2007, 35(4) : 533 538.
  • 8SATOH-ASAHARA N, SASAKI Y, WADA H, et al. A dipepti- dyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients I J]. Metabolism, 2013, 62 (3) : 347 -351.
  • 9IYER SN, DRAKE A J, WEST RL, et al. Case report of acute neerotizing pancreatitis associated with combination treatment of sitagliptin and exenatide [ J~. Endocr Pratt, 2012, 18 ( 1 ) : elO - el 3.
  • 10SCIRICA BM, BHATT DL, BRAUNWALD E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mel- litus[J~. NEnglJ Med, 2013, 369(14) :1317- 1326.

二级参考文献42

  • 1魏志军,程能能,何乐,杜文民,徐建龙,陈斌艳,王永铭.上海市药品不良反应自发呈报数据库定量信号检测系统的建立[J].复旦学报(医学版),2006,33(4):475-478. 被引量:27
  • 2卜擎燕,熊宁宁,邹建东,蒋萌,刘芳,Anna Zhao-Wong.ICH国际医学用语词典(MedDRA):药事管理的标准医学术语集[J].中国临床药理学与治疗学,2007,12(5):586-590. 被引量:38
  • 3Jadad AR,Moore RA,Carroll D. Assessing the quality of reports of randomized clinical trials:is blinding necessary[J].{H}Controlled Clinical Trials,1996,(01):1-12.
  • 4Aschner P,Kipnes MS,Lunceford JK. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes[J].{H}DIABETES CARE,2006,(12):2632-2637.
  • 5Barzilai N,Guo H,Mahoney EM. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes:a randomized,double-blind,placebo-controlled trial[J].{H}CURRENT MEDICAL RESEARCH AND OPINION,2011,(05):1049-1058.
  • 6Charbonnel B,Karasik A,Liu J. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J].{H}DIABETES CARE,2006,(12):2638-2643.
  • 7Goldstein BJ,Feinglos MN,Lunceford JK. Effect of initial combination therapy with sitagliptin,a dipeptidyl peptidase-4 inhibitor,and metformin on glycemic control in patients with type 2 diabetes[J].{H}DIABETES CARE,2007,(08):1979-1987.
  • 8Hanefeld M,Herman GA,Wu M. Once-daily sitagliptin,a dipeptidyl peptidase-4 inhibitor,for the treatment of patients with type 2 diabetes[J].{H}CURRENT MEDICAL RESEARCH AND OPINION,2007,(06):1329-1339.
  • 9Hermansen K,Kipnes M,Luo E. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin[J].{H}Diabetes Obesity & Metabolism,2007,(05):733-745.
  • 10Mohan V,Yang W,Son HY. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China,India,and Korea[J].{H}Diabetes Research and Clinical Practice,2009,(01):106-116.

共引文献24

同被引文献72

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部